BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rinatabart sesutecan (Rina-S) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rinatabart sesutecan (Rina-S)\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07604766-2708@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07604766)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: An Extension Study to Assess the Efficacy of Rina-S Compared to Treatme
 nt of Investigator's Choice in Participants With Platinum Resistant Ovaria
 n Cancer in China\nEstimated primary completion: September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076047
 66
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288177-2708@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20271122
DTEND;VALUE=DATE:20271123
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 2 readout est. (NCT07288177)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 2\, Non-Small Cell Lung C
 ancer.\nStudy: Study to Assess the Efficacy and Safety of Rina-S in Partic
 ipants With Non-small Cell Lung Cancer\nEstimated primary completion: 22 N
 ovember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rinatab
 art-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07288177
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07539311-2708@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 2 readout est. (NCT07539311)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 2.\nStudy: Study to Asses
 s the Efficacy and Safety of Rina-S in Participants With Advanced Gastroin
 testinal (GI) Cancers\nEstimated primary completion: September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/rinatabart-sesutecan-rina-
 s#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 539311
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225270-2708@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07225270)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care
  Compared to Standard of Care for Maintenance Treatment of Participants Wi
 th Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Plat
 inum-based Doublet Chemotherapy\nEstimated primary completion: October 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rinatabart-sesutec
 an-rina-s#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07225270
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-2708@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 1/2\, Non-Small Cell Lung
  Cancer.\nStudy: Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Adv
 anced Solid Tumors (GCT1184-01/ PRO1184-001)\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rina
 tabart-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07166094-2708@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07166094)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Endometrial Cancer.\n
 Study: Study to Assess the Efficacy and Safety of Rina-S Compared to Treat
 ment of Investigator's Choice in Participants With Endometrial Cancer\nEst
 imated primary completion: August 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07166094
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564141-2708@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07564141)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: Study to Assess the Efficacy and Safety of Rina-S With or Without Bevac
 izumab Compared to Investigator's Choice of Platinum-based Chemotherapy Wi
 th or Without Bevacizumab as Second-line Treatment in Participants With Re
 current Platinum-sensitive Ovarian Cancer\nEstimated primary completion: D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rinatab
 art-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07564141
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859215-2708@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07859215)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care
  Compared to Standard of Care Maintenance Treatment After First-line (1L) 
 Platinum-based Chemotherapy in Participants With Ovarian Cancer\nEstimated
  primary completion: March 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07859215
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
